NCT02303392 2025-06-10
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
Ohio State University Comprehensive Cancer Center
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
GSO Global Clinical Research BV
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Washington University School of Medicine